{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:45:46Z","timestamp":1794620746512,"version":"4.9.1"},"reference-count":10,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,15]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The prognostic impact of achieving and in particular maintaining measurable residual disease (MRD) negativity in multiple myeloma is now established; therefore, identifying among MRD-negative patients the ones at higher risk of losing MRD negativity is of importance. We analyzed predictors of unsustained MRD negativity in patients enrolled in the FORTE trial (NCT02203643). MRD was performed by multiparameter flow cytometry (sensitivity of 10\u22125) at premaintenance and every 6 months thereafter. The cumulative incidence (CI) of MRD resurgence and\/or progression was analyzed in MRD-negative patients. A total of 306 of 474 (65%) MRD-negative patients were analyzed. After a median follow-up of 50.4 months from MRD negativity, 185 of 306 (60%) patients were still MRD negative and progression free, 118 (39%) lost their MRD-negative status, and 3 patients (1%) died without progression. Amp1q vs normal (4-year CI, 63% vs 34), \u22652 concomitant high-risk cytogenetic abnormalities vs 0 (4-year CI, 59% vs 33%), circulating tumor cells at baseline (high vs low at 4-year CI, 62% vs 32%), and time-to-reach MRD negativity postconsolidation vs preconsolidation (4-year CI, 46% vs 35%) were associated with a higher risk of unsustained MRD negativity in a multivariate Fine-Gray model. During the first 2 years of maintenance, patients receiving carfilzomib-lenalidomide vs lenalidomide alone had a lower risk of unsustained MRD negativity (4-year CI, 20% vs 33%).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022080","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T21:41:15Z","timestamp":1701726075000},"page":"592-596","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma"],"prefix":"10.1182","volume":"143","author":[{"given":"Mattia","family":"D\u2019Agostino","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy"},{"name":"2Division of Hematology, Azienda Ospedaliero\u2013Universitaria Citt\u00e0 della Salute e della Scienza di Torino, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3785-9824","authenticated-orcid":false,"given":"Giuseppe","family":"Bertuglia","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy"},{"name":"2Division of Hematology, Azienda Ospedaliero\u2013Universitaria Citt\u00e0 della Salute e della Scienza di Torino, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0744-6390","authenticated-orcid":false,"given":"Delia","family":"Rota-Scalabrini","sequence":"additional","affiliation":[{"name":"3Medical Oncology Department Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Belotti","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mor\u00e8","sequence":"additional","affiliation":[{"name":"5Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, Universit\u00e0 Politecnica delle Marche, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"6University of Milan, Milan, Italy; and Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-180X","authenticated-orcid":false,"given":"Stefania","family":"Oliva","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Azienda Ospedaliero\u2013Universitaria Citt\u00e0 della Salute e della Scienza di Torino, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ledda","sequence":"additional","affiliation":[{"name":"7Ematologia\/Centro Trapianti Midollo Osseo, Ospedale A. Businco, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"Grasso","sequence":"additional","affiliation":[{"name":"8Azienda Ospedaliera S. Croce-Carle, Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[{"name":"9Hematology and Bone Marrow Transplant, Hospital Cardinale G. Panico, Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-9421","authenticated-orcid":false,"given":"Sonia","family":"Ronconi","sequence":"additional","affiliation":[{"name":"10IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda Donatella","family":"Vincelli","sequence":"additional","affiliation":[{"name":"11Divisione di Ematologia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelvio","family":"Ballanti","sequence":"additional","affiliation":[{"name":"12Sezione di Ematologia e Immunologia Clinica, Ospedale Santa Maria della Misericordia, localit\u00e0 Sant\u2019Andrea delle Fratte, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Velluti","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cellini","sequence":"additional","affiliation":[{"name":"13U.O.C. Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-6891","authenticated-orcid":false,"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[{"name":"14Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico S. Maria alle Scotte, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-9754","authenticated-orcid":false,"given":"Angelo D.","family":"Palmas","sequence":"additional","affiliation":[{"name":"15Struttura Complessa Ematologia, Ospedale San Francesco, Azienda Sanitaria Locale Nuoro, Nuoro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gamberi","sequence":"additional","affiliation":[{"name":"16Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[{"name":"17IRCCS Azienda Ospedaliero\u2013Universitaria di Bologna, Istituto di Ematologia Ser\u00e0gnoli, Bologna, Italy"},{"name":"18Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Paris","sequence":"additional","affiliation":[{"name":"19Division of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-5324","authenticated-orcid":false,"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[{"name":"20Hematology Section, Department of Medicine, Padua University School of Medicine, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[{"name":"21Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-6770","authenticated-orcid":false,"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy"},{"name":"2Division of Hematology, Azienda Ospedaliero\u2013Universitaria Citt\u00e0 della Salute e della Scienza di Torino, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-6594","authenticated-orcid":false,"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[{"name":"22Department of Precision and Regenerative Medicine and Ionian Area, Aldo Moro University School of Medicine, Bari, Italy"},{"name":"23Hematology and Stem Cell Transplantation Unit, Azienda Ospedaliero\u2013Universitaria Consorziale Policlinico, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy"},{"name":"2Division of Hematology, Azienda Ospedaliero\u2013Universitaria Citt\u00e0 della Salute e della Scienza di Torino, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2024021516233644200_bib1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"10192","key":"2024021516233644200_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"2024021516233644200_bib3","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024021516233644200_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024021516233644200_bib5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","article-title":"Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2024021516233644200_bib6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"27","key":"2024021516233644200_bib7","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024021516233644200_bib8","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024021516233644200_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","article-title":"MRD assessment in multiple myeloma: progress and challenges","volume":"16","author":"Bertamini","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"suppl 1","key":"2024021516233644200_bib10","doi-asserted-by":"crossref","first-page":"10144","DOI":"10.1182\/blood-2022-160451","article-title":"Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with\u00a0high-risk cytogenetic abnormalities (HRCA) in the Griffin and Master studies","volume":"140","author":"Callander","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/7\/592\/2213726\/blood_bld-2023-022080-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/7\/592\/2213726\/blood_bld-2023-022080-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:23:48Z","timestamp":1708014228000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/7\/592\/506496\/Predictors-of-unsustained-measurable-residual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022080","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}